AstraZeneca Annual Report and Form 20-F 2002 Additional Information for US Investors www.
com 113 Additional Information for US Investors Differences between UK and US 2002, under US GAAP, goodwill was required Pension and post-retirement benefits accounting principles to be capitalised and amortised.
Now, instead There are four main differences between of being amortised, goodwill is tested current UK GAAP and US GAAP in The accompanying consolidated financial annually for impairment.
Amortisation accounting for pension costs: statements included in this Annual Report are charged under UK GAAP is added back in prepared in accordance with UK GAAP.
the reconciliation of net income.
The i US GAAP requires measurements of plan Certain significant differences between UK intangible recognised as assembled assets and obligations to be made as at GAAP and US GAAP which affect workforce has been reclassified as goodwill.
the date of the financial statements or a AstraZenecas net income and shareholders date not more than three months prior to equity are set out below.
Identifiable intangible assets, which principally that date.
Under UK GAAP, calculations include patents, know-how and product may be based on the results of the latest Purchase accounting adjustments registrations, are amortised over their actuarial valuation: Under UK GAAP the merger of Astra and estimated useful lives which vary between 5 Zeneca was accounted for as a merger of years and 20 years with a weighted average ii US GAAP mandates a particular actuarial equals pooling-of-interests.
Under US life of approximately 13 years.
method the projected unit credit GAAP the merger was accounted for as the method and requires that each acquisition of Astra by Zeneca using At 31 December 2002 and 2001, significant assumption necessary to purchase accounting.
Under purchase shareholders equity includes capitalised determine annual pension cost reflects accounting, the cost of the investment is goodwill of $13,600m and $12,169m best estimates solely with regard to that calculated at the market value of the shares respectively net of amortisation and individual assumption.
UK GAAP does issued together with other incidental costs impairment of $2,383m and $2,180m and not mandate a particular method, but and the assets and liabilities of the acquired capitalised identifiable intangible assets of requires that the method and entity are recorded at fair value.
As a result of $9,433m and $9,789m respectively net of assumptions taken as a whole should be the fair value exercise, increases in the values amortisation and impairment of $4,566m and compatible and lead to the actuarys best of Astras tangible fixed assets and inventory $3,475m.
Goodwill on businesses disposed estimate of the cost of providing the were recognised and values attributed to their of is charged to the gain or loss on disposal.
benefits promised: in-process research and development, existing products and assembled work force, On disposal of a business, the gain or loss iii under US GAAP, a negative pension cost together with appropriate deferred taxation under US GAAP may differ from that under may arise where a significant effects.
The difference between the cost of UK GAAP due principally to goodwill unrecognised net asset or gain exists at investment and the fair value of the assets capitalised and amortised, together with the the time of implementation.
This is and liabilities of Astra was recorded as appropriate share of other differences required to be amortised on a straight-line goodwill.
The amount allocated to in-process between UK and US accounting principles basis over the average remaining service research and development was, as required recognised previously.
Under UK GAAP, by US GAAP, expensed immediately in the AstraZenecas policy is not to recognise first reporting period after the business Capitalisation of interest pension credits in its financial statements combination.
Fair value adjustments to the AstraZeneca does not capitalise interest in its unless a refund of, or reduction in, recorded amount of inventory were expensed financial statements.
US GAAP requires contributions is likely: and in the period the inventory was utilised.
interest incurred as part of the cost of Additional amortisation and depreciation have constructing fixed assets to be capitalised iv under US GAAP, a minimum pension also been recorded in respect of the fair value and amortised over the life of the asset.
liability is recognised through other adjustments to tangible and intangible assets comprehensive income in certain and the resulting goodwill.
Dividends circumstances when there is a deficit of Under UK GAAP Ordinary Share dividends plan assets relative to the projected In the consolidated financial statements proposed are provided for in the year in benefits obligation.
Under UK GAAP, prepared under UK GAAP, goodwill arising on respect of which they are recommended by there is no such requirement.
acquisitions made prior to 1 January 1998 the Board of Directors for approval by the accounted for under the purchase method shareholders.
Under US GAAP such has been eliminated against shareholders dividends are not provided for until declared equity.
Under the requirements of UK by the Board.
Financial Reporting Standard 10 Goodwill and Intangible Assets, goodwill on Deferred taxation acquisitions made after 1 January 1998 is Deferred taxation is provided on a full liability capitalised and amortised over its estimated basis under US GAAP, which permits useful life which is generally presumed not to deferred tax assets to be recognised if their exceed 20 years.
UK GAAP requires that on realisation is considered to be more likely than subsequent disposal or termination of a not.
Under current UK GAAP, full provision is previously acquired business, any goodwill also made although there are a number of previously taken directly to shareholders different bases on which this calculation is equity is then charged in the income made, eg rolled over capital gains.
statement against the profit or loss on disposal or termination.
Up until 1 January AstraZeneca Annual Report and Form 20-F 2002 Additional Information for US Investors www.
com 114 Additional Information for US Investors continued Differences between UK and US the income statement in subsequent periods comprise current asset investments held as accounting principles continued until all disposal obligations and readily disposable stores of value.
Under commitments have been completed.
95 cash equivalents, comprising Restructuring costs short term highly liquid investments, generally Under UK GAAP, provisions are made for Current assets and liabilities with original maturities of three months or less, restructuring costs once a detailed formal In the Groups financial statements prepared are grouped together with cash: short term plan is in place and valid expectations have under UK GAAP, no cost is accrued for the borrowings repayable on demand would not been raised in those affected that the share options awarded to employees under be included within cash and cash equivalents restructuring will be carried out.
US GAAP the Zeneca 1994 Executive Share Option and movements on those borrowings would requires a number of specific criteria to be Scheme, the AstraZeneca Share Option be included in financing activities.
met before such costs can be recognised as Plan, and the AstraZeneca Savings-Related an expense.
Among these are the Share Option Scheme as the exercise price is New accounting standards adopted requirements that the costs incurred are equivalent to the market value at the date of Statement of Financial Accounting Standards incremental to other costs incurred by the grant.
Under US GAAP the cost is calculated SFAS No.
141 Business Combinations and company, or represent amounts to be as the difference between the option price SFAS No.
142 Goodwill and Other Intangible incurred under contractual obligations which and the market price at the date of grant or, Assets were issued in July 2001 and are are not associated with or do not benefit for variable plans, at the end of the reporting effective for accounting periods commencing activities that will be continued.
Also, all period until measurement date.
Under the on or after 15 December 2001.
Under SFAS significant actions arising from a restructuring requirements of APB Opinion No.
141, all business combinations initiated and their completion dates must be identified compensation cost would be amortised over after 30 June 2001 must be accounted for by the balance sheet date.
To the extent that the period from the date the options are using the purchase method.
The pooling of restructuring costs are related to the activities granted to the date they are first exercisable.
interest method is no longer permitted.
of the acquired company, US GAAP allows Under US GAAP in the net income Intangible assets arising on acquisitions are them to be recognised as a liability upon reconciliation, the Group has adjusted for required to be amortised to residual values acquisition.
stock compensation costs and calculated over their estimated useful lives unless they under APB Opinion No.
25. are regarded as having indefinite useful lives, Software costs in which case they are tested annually for Under UK GAAP, AstraZeneca capitalises Statement of cash flows: Basis of impairment.
Goodwill, arising on a certain defined software costs.
Under US preparation combination of business, is tested for GAAP software costs are generally AstraZenecas Statement of Group Cash impairment annually in lieu of amortisation.
capitalised and amortised over three to five Flow is prepared in accordance with United SFAS No.
142 requires that goodwill and years.
Kingdom Financial Reporting Standard 1 intangible assets acquired prior to 1 July 2001 Revised 1996 FRS 1, whose objective should continue to be amortised and tested Foreign exchange and principles are similar to those set out in for impairment until the adoption of the Under UK GAAP, unrealised gains and losses SFAS No.
142 an on foreign currency transactions to hedge The principal differences between the impairment test must be carried out on all anticipated, but not firmly committed, foreign standards relate to classification.
Under FRS intangible assets with indefinite useful lives currency transactions may be deferred and 1, the Company presents its cash flows for a and goodwill.
Any impairment loss identified accounted for at the same time as the operating activities: b dividends received on the date of adoption of SFAS No.
Under US GAAP from joint ventures and associates: c returns should be accounted for as a cumulative such deferral is not permitted except in on investments and servicing of finance: d effect of a change in accounting principle.
tax paid: e capital expenditure and financial At the same time, the estimated useful lives investment: f acquisitions and disposals: g of amortised intangible assets must be Derivative instruments and hedging dividends paid to shareholders: h reviewed.
activities management of liquid resources: and i Under US GAAP, all derivative instruments financing.
95 requires only three Adoption of these new accounting standards should be recognised as assets or liabilities in categories of cash flow activity being a has resulted in an estimated increase in net the balance sheet at fair value.
Gains and operating: b investing: and c financing.
income of $755m including amortisation losses are recognised in net income unless charged under UK GAAP of $55m.
Initial they are regarded as hedges.
Under UK Cash flows from taxation, returns on adoption of SFAS No.
142 did not result in an GAAP, these instruments are measured at investments and servicing of finance and impairment charge, nor was there any cost and gains or losses deferred until the dividends received from joint ventures and impairment at the subsequent annual test.
associates under FRS 1 would be included as Had goodwill not been amortised in 2001, net operating activities under SFAS No.
95: income would have increased from $1,397m Deferred income capital expenditure and financial investment to $2,125m 2000 $865m to $1,716m with a Under UK GAAP, profits or losses from the and acquisitions and disposals would be corresponding increase in basic and diluted sale of product related intangible assets are included as investing activities: and earnings per share from $0.77 to $1.21 2000 classified in other operating income and are distributions would be included as a financing $0.49 to $0.97.
No changes were made to stated after taking account of product activity under SFAS No.
Under FRS 1 estimated useful lives of intangible assets.
disposal costs and costs of minor cash comprises cash in hand and deposits outstanding obligations.
Under US GAAP, repayable on demand, less overdrafts SFAS No.
144 Accounting for the such profits are deferred and recognised in repayable on demand: and liquid resources Impairment or Disposal of Long-Lived Assets AstraZeneca Annual Report and Form 20-F 2002 Additional Information for US Investors www.
com 115 addresses financial accounting and reporting for the impairment or disposal of long-lived assets and supersedes SFAS No.
121, Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed of and the accounting and reporting provisions of APB Opinion No.
30, Reporting the Results of Operations Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions, for the disposal of a segment of a business.
It is effective for accounting periods beginning on or after 15 December 2001.
144 did not have a material effect.
New accounting standards not yet adopted SFAS No.
143 Accounting for Asset Retirement Obligation addresses the accounting and reporting for obligations associated with the retirement of long-lived assets and the associated asset retirement costs.
It is effective for accounting periods beginning on or after 15 June 2002.
143 is not expected to have a material effect.
146 Accounting for Costs Associated with Exit or Disposal Activities, issued on 30 July 2002 requires costs associated with exit or disposal activities to be recognised when the costs are incurred rather than at the date of commitment to an exit or disposal plan.
The provisions are effective for disposals initialised after 31 December 2002 and restatement of prior periods is not required.
146 may apply to future activities which are not currently envisaged it is not possible to assess the impact of SFAS No.
148 Accounting for Stock Based Compensation Transition and Disclosure an amendment of FASB Statement No.
123 permits two additional transition methods for entities that adopt the fair value based method of accounting for stock-based employee compensation.
The Statement also requires new disclosures about the ramp-up effect of stock-based employee compensation on reported results and that those effects be disclosed more prominently by specifying the form, content and location of those disclosures.
The transition guidance and annual disclosure provisions of SFAS No.
148 are effective for fiscal years ending after 15 December 2002.
AstraZeneca has not yet determined whether it will adopt the transition provisions of SFAS No.
com 116 Additional Information for US Investors continued Differences between UK and US accounting principles continued Introduction As a result of the significant difference between the UK GAAP and US GAAP treatment of the combination of Astra and Zeneca in the year of acquisition, and in the results of preceding periods, condensed statements of operations and cash flow under US GAAP have been prepared for the benefit of US investors.
The following is a summary of the material adjustments to net income and shareholders equity which would have been required if US GAAP had been applied instead of UK GAAP.
As noted on page 62, 2001 and 2000 net income and shareholders equity under UK GAAP have been restated under FRS19 Deferred Tax.
On this basis the deferred tax adjustment below as been restated for those years.
Net income 2002 2001 2000 $m $m $m Net income, as shown in the consolidated statements of income before exceptional items restated 3,186 3,044 2,858 Exceptional items after tax 350 138 581 Net income for the period under UK GAAP restated 2,836 2,906 2,277 Adjustments to conform to US GAAP Purchase accounting adjustments including goodwill and intangibles Deemed acquisition of Astra Amortisation and other acquisition adjustments 864 1,514 1,756 Others 55 20 Capitalisation, less disposals and amortisation of interest 46 57 45 Deferred taxation On fair values of Astra 239 249 284 Others restated 99 198 115 Pension expense 50 33 50 Post-retirement benefits plan amendment 4 44 Software costs 46 10 98 Restructuring costs 22 97 Share based compensation 33 7 33 Fair value of derivative financial instruments 93 18 Deferred income recognition 61 75 Unrealised losses on foreign exchange and others 1 10 2 Net income before cumulative effect of change in accounting policy 2,307 1,365 865 Cumulative effect of change in accounting policy, net of tax, on adoption of SFAS No 133 32 Net income in accordance with US GAAP 2,307 1,397 865 AstraZeneca Annual Report and Form 20-F 2002 Additional Information for US Investors www.
com 117 Differences between UK and US accounting principles continued US GAAP Condensed Consolidated Statement of Operations 2002 2001 2000 For the years ended 31 December $m $m $m Sales 17,841 16,222 15,583 Cost of sales 4,520 4,198 3,960 Distribution costs 141 122 210 Research and development 3,069 2,687 2,620 Selling, general and administrative expenses 6,165 5,219 4,861 Acquisition related costs 224 419 Amortisation of intangibles and goodwill 1,052 1,769 2,043 Other income 308 283 223 Operating income 3,202 2,286 1,693 Net interest income 140 188 183 Income from continuing operations before taxation 3,342 2,474 1,876 Taxes on income from continuing operations 1,035 1,109 969 Net income from continuing operations 2,307 1,365 907 Discontinued operations: Net income from discontinued operations 42 Net income before cumulative effect of change in accounting policy 2,307 1,365 865 Cumulative effect of change in accounting policy on adoption of SFAS No 133 32 Net income for the year 2,307 1,397 865 Weighted average number of $0.25 Ordinary Shares in issue millions of shares 1,733 1,758 1,768 Dilutive impact of share options outstanding millions of shares 2 32 Diluted weighted average number of $0.25 Ordinary Shares in accordance with US GAAP millions of shares 1,735 1,761 1,770 Net income per $0.25 Ordinary Share and ADS before change in accounting policy in accordance with US GAAP basic and diluted $ $1.33 $0.77 $0.49 Net income per $0.25 Ordinary Share and ADS after change in accounting policy in accordance with US GAAP basic and diluted $ $1.33 $0.79 $0.49 2002 2001 2000 Net income from continuing operations per $0.25 Ordinary Share and ADS in accordance with US GAAP basic and diluted $ $1.33 $0.79 $0.51 Net loss from discontinued operations per $0.25 Ordinary Share and ADS in accordance with US GAAP basic and diluted $ $0.02 The dividend in specie in 2000 in respect of the demerger of Zeneca Agrochemicals under US GAAP amounted to $836m, after realised exchange gains on the translation of foreign currency financial statements of $297m.
As noted on page 62, cash settlement discounts have been reclassified from cost of sales to sales.
Comparative information for 2001 and 2000 has also been reclassified for consistency of presentation.
com 118 Additional Information for US Investors continued Differences between UK and US accounting principles continued US GAAP Statement of Comprehensive Income 2002 2001 2000 For the years ended 31 December $m $m $m Net income for the year 2,307 1,397 865 Exchange gains losses net of tax 2,919 1,473 2,184 Exchange realised on demerger of Zeneca Agrochemicals 297 Other movements 73 2 Total Comprehensive Income 5,153 76 1,618 Other movements in 2002 include the recognition of a minimum liability under SFAS 87 of $45m.
The cumulative exchange gains and losses net of tax on the translation of foreign currency financial statements under US GAAP are set out in the following note: 2002 2001 2000 For the years ended 31 December $m $m $m Balance at 1 January 4,318 2,845 364 Movement in year 2,919 1,473 2,481 Balance at 31 December 1,399 4,318 2,845 Stock compensation In the Groups financial statements prepared under UK GAAP, no cost is accrued for the share options awarded to employees under the Zeneca 1994 Executive Share Option Scheme, the AstraZeneca Share Option Plan, and the AstraZeneca Savings-Related Share Option Scheme as the exercise price is equivalent to the market value at the date of grant.
Under US GAAP the cost is calculated as the difference between the option price and the market price at the date of grant or, for variable plans, at the end of the reporting period until measurement date.
Under the requirements of APB Opinion No.
25 any compensation cost would be amortised over the period from the date the options are granted to the date they are first exercisable.
Under US GAAP in the net income reconciliation, the Group has adjusted for stock compensation costs as calculated under APB Opinion No 25, SFAS No.
123 sets out an alternative methodology for recognising the compensation cost based on the fair value at grant date.
Had the Group adopted this methodology, the incremental effect on net income under US GAAP is shown below: 2002 2001 2000 $m $m $m Net income under US GAAP as reported 2,307 1,397 865 Compensation cost after adjusting for APB 25 credit of $33m 155 76 46 Pro forma net income 2,152 1,321 819 Pro forma net income per $0.25 Ordinary Share and ADS in accordance with US GAAP basic and diluted : As reported $ $1.33 $0.79 $0.49 Pro forma $ $1.24 $0.75 $0.46 The fair value of options granted is estimated, based on the stock price at the grant date, using the Black-Scholes option pricing model with the following assumptions: 2002 2001 2000 Dividend yield 1.6% 1.5% 2.0% Expected volatility 30.0% 20.0% 20.0% Risk-free interest rate 5.2% 4.2% 5.9% Expected lives: 1994 Scheme 6.0 years Expected lives: AstraZeneca Share Option Plan 6.0 years 6.0 years 6.0 years Expected lives: SAYE Scheme 4.3 years 4.3 years 4.6 years In the initial phase-in period, the effects of applying SFAS No.
123 for disclosing compensation cost may not be representative of the effects on pro forma net income and earnings per share for future years.
com 119 Differences between UK and US accounting principles continued Pension and post-retirement benefits For the purposes of US GAAP, the pension costs of the major UK retirement plan and of the retirement plans of the major non-UK subsidiaries have been restated in the following tables in accordance with the requirements of SFAS No.
These plans comprise a substantial portion of the actuarial liabilities of all AstraZeneca retirement plans.
The changes in projected benefit obligations, plan assets and details of the funded status of these retirement plans, together with the changes in the accumulated other post-retirement benefit obligations, under SFAS No.
132 are as follows: Other post-retirement Pension benefits benefits Change in projected benefit obligation 2002 2001 2002 2001 $m $m $m $m Benefit obligation at beginning of year 4,337 4,188 205 197 Service cost 114 102 8 7 Interest cost 263 243 14 14 Participant contributions 18 17 Plan amendments 11 Actuarial gain loss 80 75 23 1 Special termination benefits 12 19 Settlement and curtailment 24 Benefits paid 206 198 19 14 Exchange 408 98 3 2 Benefit obligation at end of year 5,026 4,337 210 205 Other post-retirement Pension benefits benefits Change in plan assets 2002 2001 2002 2001 $m $m $m $m Fair value at 1 January 3,753 3,803 Actual return on plan assets 142 45 16 Group contribution 284 170 161 Participant contributions 18 17 Settlement and curtailment Benefits paid 205 198 12 Exchange 330 84 Fair value of plan assets at end of year 4,038 3,753 133 Funded status of plans 988 584 77 205 Unrecognised net loss profit 938 396 Prior service cost not recognised 29 35 Unrecognised net obligation on implementation 3 6 18 147 77 205 Adjustments to recognise minimum liability Intangible assets 45 Accumulated other comprehensive income 45 Accrued benefit liability 108 147 77 205 AstraZeneca Annual Report and Form 20-F 2002 Additional Information for US Investors www.
com 120 Additional Information for US Investors continued Differences between UK and US accounting principles continued At 31 December 2002, the projected benefit obligation, accumulated benefit obligation and fair value of the plan assets in respect of the retirement plans above with accumulated benefit obligations in excess of plan assets were $4,249m, $3,557m and $3,296m, 2001 $97m, $73m and $nil respectively.
Assumed discount rates and rates of increase in remuneration used in calculating the projected benefit obligations together with long term rates of return on plan assets vary according to the economic conditions of the country in which the retirement plans are situated.
The weighted average rates used for calculation of year end benefit obligations and forecast benefit cost in the main retirement plans and other benefit obligations for SFAS No.
132 purposes were as follows: Pension benefits Other post-retirement benefits 2002 2001 2000 2002 2001 2000 % %% % %% Discount rate 5.8 6.0 5.6 6.6 7.1 7.1 Long term rate of increase in remuneration 4.1 4.4 4.4 4.8 n a n a Expected long term return on assets 6.4 6.5 6.2 7.8 n a n a The Group has assumed a long term rate of increase in healthcare costs of 11.0%, reducing to 5.0%.
Pension benefits Other post-retirement benefits 2002 2001 2000 2002 2001 2000 $m $m $m $m $m $m Net periodic cost Service cost present value of benefits accruing during the year 114 102 152 8 710 Interest cost on projected benefit obligations 263 243 301 14 14 17 Expected return on assets 263 242 322 Net amortisation and deferral 28 39 46 1 2 1 Net periodic cost for the year 142 142 177 21 19 26 It is estimated that a 1 percentage point change in the weighted average healthcare costs trend would have the following effects on the accumulated benefit obligation and net periodic cost at 31 December 2002: 1 percentage point increase decrease $m $m Accumulated benefit obligation 10 9 Net periodic cost 2 1 Taxation 2002 2001 2000 Years ended 31 December $m $m $m Taxes on income from continuing operations UK taxation Corporation tax 165 147 79 Double taxation relief 7 4 42 Deferred 40 10 27 Overseas taxation Overseas taxes 921 831 956 Deferred taxation 84 125 Share of taxation of joint ventures and associates 3 Taxes on income from continuing operations 1,035 1,109 969 AstraZeneca Annual Report and Form 20-F 2002 Additional Information for US Investors www.
com 121 Differences between UK and US accounting principles continued The table below reconciles the UK statutory tax charge to the Groups actual charge on income from continuing operations.
2002 2001 2000 Years ended 31 December $m $m $m Income on continuing operations 3,342 2,506 1,876 Taxation charge at UK corporation tax rate of 30% for 2002 30% for 2001, 30% for 2000 1,002 751 563 Acquisition related items 429 Goodwill, Advanta, and Salick Health Care impairment 190 576 Net effect of different rates and eligible costs in other jurisdictions 21 43 86 Exceptional items 105 419 Other 51 203 132 Tax on income from continuing operations 1,035 1,109 969 In 2002, claims amounting to $43m 2001 $109m for tax relief arising as a result of a restructuring of the AMI joint venture in 1998 were made.
Under US GAAP, these reliefs are adjusted against the goodwill arising on the restructuring and included in other adjustments.
Shareholders equity 2002 2001 $m $m Total shareholders equity under UK GAAP restated 11,172 9,586 Adjustments to conform to US GAAP Purchase accounting adjustments including goodwill and intangibles Deemed acquisition of Astra Goodwill 12,692 11,062 Tangible and intangible fixed assets 7,707 8,139 Others 86 31 Capitalisation, less disposals and amortisation of interest 238 192 Deferred taxation On fair value of Astra 2,305 2,313 Others restated 159 68 Dividend 808 820 Pension expense 271 162 Post-retirement benefits plan amendment 24 28 Software costs capitalised 64 110 Fair value of derivative financial instruments 99 50 Deferred income recognition 14 75 Others 90 58 Shareholders equity in accordance with US GAAP 30,183 27,402 AstraZeneca Annual Report and Form 20-F 2002 Additional Information for US Investors www.
com 122 Additional Information for US Investors continued Differences between UK and US accounting principles continued US GAAP Condensed Consolidated Statement of Cash Flows 2002 2001 2000 For the years ended 31 December $m $m $m Cash flows from operating activities 4,833 3,126 3,554 Cash flows from investing activities Movement in short term investments and fixed deposits 806 260 608 New fixed asset investments 1 5 3 Disposal of fixed assets 66 44 37 Acquisitions and disposals 44 740 Capital expenditure 1,608 1,582 1,460 Net cash outflows from investing activities 2,349 1,327 1,294 Net cash flow before financing 2,484 1,799 2,260 Cash flows from financing activities Equity dividends paid 1,234 1,236 1,220 Repurchase of AstraZeneca PLC Ordinary Shares 1,154 994 334 Net decrease increase in short term borrowings 13 7 67 Loans repaid new loans 105 28 3 Repayment of lease finance 2 Net cash outflows from financing activities 2,506 2,195 1,620 Decrease increase in cash 22 396 640 Cash: At 1 January 510 908 262 Decrease increase in cash 22 396 640 Exchange movements 36 2 6 At 31 December 524 510 908 1 Interest paid was $96m in 2002, $84m in 2001, $145m in 2000.
